TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Olema Pharmaceuticals ( (OLMA) ) has issued an update.
Olema Pharmaceuticals announced the termination of its ATM Prospectus, effective November 18, 2025, which was related to the sale of its common stock in an ‘at-the-market’ offering. The termination means the company will not sell its common stock under the existing Sales Agreement with TD Securities (USA) LLC until a new prospectus or registration statement is filed, although the Sales Agreement itself remains active.
The most recent analyst rating on (OLMA) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Olema Pharmaceuticals stock, see the OLMA Stock Forecast page.
Spark’s Take on OLMA Stock
According to Spark, TipRanks’ AI Analyst, OLMA is a Neutral.
Olema Pharmaceuticals faces substantial financial challenges with zero revenue and increasing losses, necessitating external funding. The technical analysis indicates some recent positive momentum, but the stock remains speculative due to negative profitability. The strategic collaboration with Novartis offers a positive outlook, potentially enhancing market position and supporting long-term growth. These factors collectively result in a moderate overall stock score.
To see Spark’s full report on OLMA stock, click here.
More about Olema Pharmaceuticals
Average Trading Volume: 1,193,197
Technical Sentiment Signal: Buy
Current Market Cap: $576.7M
For a thorough assessment of OLMA stock, go to TipRanks’ Stock Analysis page.